Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Low RAAS inhibitor dosing linked to MACE risk

Key clinical point: Suboptimal RAAS inhibitor dosing in CKD and heart failure linked to increased major adverse cardiac event and mortality risk.

Major finding: Mortality and MACE rates were significantly higher in patients on suboptimal doses of renin-angiotensin-aldosterone system inhibitors.

Study details: Observational study in 100,572 people with nondialysis chronic kidney disease and 13,113 with new-onset heart failure.

Disclosures: The study was funded by AstraZeneca. One author was an employee and stockholder of AstraZeneca, and five authors declared funding and support from the pharmaceutical sector, including AstraZeneca.


Linde C et al. J Am Heart Assoc. 2019 Nov 12. doi: 10.1161/JAHA.119.012655.